Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
0.9800 unch (unch) 02/20/25 [NASDAQ]
0.9700 x 2 1.0100 x 1
Realtime by (Cboe BZX)
0.9700 x 2 1.0100 x 1
Realtime 0.9700 -0.0100 (-) 16:05 ET
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9600
Day High
1.0100
Open 1.0100
Previous Close 0.9800 0.9800
Volume 196,736 196,736
Avg Vol 199,847 199,847
Stochastic %K 13.67% 13.67%
Weighted Alpha -85.59 -85.59
5-Day Change -0.0694 (-6.74%) -0.0694 (-6.74%)
52-Week Range 0.8900 - 9.6500 0.8900 - 9.6500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,701
  • Shares Outstanding, K 2,766
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,300 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.20
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.98
  • Most Recent Earnings $-2.32 on 11/12/24
  • Next Earnings Date 03/25/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -2.39
  • Number of Estimates 1
  • High Estimate -2.39
  • Low Estimate -2.39
  • Prior Year -3.75
  • Growth Rate Est. (year over year) +36.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8900 +7.93%
on 02/12/25
Period Open: 1.4800
1.6500 -41.78%
on 01/24/25
-0.5194 (-35.09%)
since 01/17/25
3-Month
0.8900 +7.93%
on 02/12/25
Period Open: 2.4400
3.3000 -70.89%
on 12/12/24
-1.4794 (-60.63%)
since 11/20/24
52-Week
0.8900 +7.93%
on 02/12/25
Period Open: 6.6000
9.6500 -90.05%
on 04/16/24
-5.6394 (-85.45%)
since 02/20/24

Most Recent Stories

More News
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) 

PALI : 0.9800 (+0.37%)
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

PALI : 0.9800 (+0.37%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.0550 (-0.47%)
AREC : 0.5743 (-2.25%)
OTLK : 1.6400 (-3.24%)
AMIX : 2.93 (+2.09%)
CNSP : 0.0750 (-10.50%)
PALI : 0.9800 (+0.37%)
NVNO : 3.82 (+6.41%)
HURA : 3.30 (+3.77%)
GRI : 0.4352 (-17.90%)
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

PALI : 0.9800 (+0.37%)
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

PALI : 0.9800 (+0.37%)
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

PALI : 0.9800 (+0.37%)
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

PALI : 0.9800 (+0.37%)
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PALI : 0.9800 (+0.37%)
Palisade Bio, Inc. Appoints Brian G. Feagan, MD, to Clinical Advisory Board

Palisade Bio appoints Dr. Brian G. Feagan to its Clinical Advisory Board to enhance its autoimmune therapeutic development.Quiver AI SummaryPalisade Bio, Inc. has announced the appointment of Dr. Brian...

PALI : 0.9800 (+0.37%)
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

PALI : 0.9800 (+0.37%)

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 1.0709
2nd Resistance Point 1.0455
1st Resistance Point 1.0109
Last Price 0.9800
1st Support Level 0.9509
2nd Support Level 0.9255
3rd Support Level 0.8909

See More

52-Week High 9.6500
Fibonacci 61.8% 6.3037
Fibonacci 50% 5.2700
Fibonacci 38.2% 4.2363
Last Price 0.9800
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements